tiprankstipranks
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
US Market
ALNY
Alnylam Pharma
RESEARCH TOOLSreports
Want to see ALNY full AI Analyst Report?

Alnylam Pharma (ALNY) Stock Forecast & Price Target

1,543 Followers
See the Price Targets and Ratings of:

ALNY Analyst Ratings

Strong Buy
20Ratings
Strong Buy
19 Buy
1 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Alnylam
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALNY Stock 12 Month Forecast

Average Price Target

$458.29
▲(48.00% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $458.29 with a high forecast of $550.00 and a low forecast of $380.00. The average price target represents a 48.00% change from the last price of $309.66.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"294":"$294","551":"$551","358.25":"$358.3","422.5":"$422.5","486.75":"$486.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":550,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$550.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":458.29411764705884,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$458.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$380.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[294,358.25,422.5,486.75,551],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,301.67,320.7723076923077,339.87461538461537,358.9769230769231,378.0792307692308,397.1815384615385,416.2838461538462,435.38615384615383,454.48846153846154,473.59076923076924,492.6930769230769,511.7953846153846,530.8976923076923,{"y":550,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,301.67,313.7180090497738,325.7660180995475,337.8140271493213,349.86203619909503,361.9100452488688,373.95805429864254,386.0060633484163,398.05407239819004,410.1020814479638,422.15009049773755,434.19809954751133,446.2461085972851,{"y":458.29411764705884,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,301.67,307.6953846153846,313.72076923076924,319.74615384615385,325.77153846153846,331.79692307692306,337.82230769230773,343.84769230769234,349.87307692307695,355.89846153846156,361.92384615384617,367.9492307692308,373.9746153846154,{"y":380,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":322.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":447,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":460.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":456.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":454.56,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":397.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":339.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.07,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.73,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":296.11,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":295.63,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":301.67,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$550.00Average Price Target$458.29Lowest Price Target$380.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on ALNY
Eric Joseph
Citi
Citi
$380
Buy
22.72%
Upside
Reiterated
07/16/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)
Stifel Nicolaus Analyst forecast on ALNY
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$444
Buy
43.38%
Upside
Reiterated
07/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (NASDAQ: ISRG), Alnylam Pharma (NASDAQ: ALNY) and Esperion (NASDAQ: ESPR)
Bank of America Securities Analyst forecast on ALNY
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$460→$410
Buy
32.40%
Upside
Reiterated
07/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Krystal Biotech (NASDAQ: KRYS)
H.C. Wainwright Analyst forecast on ALNY
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$470→$485
Buy
56.62%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Immuneering (NASDAQ: IMRX), Vera Therapeutics (NASDAQ: VERA) and Alnylam Pharma (NASDAQ: ALNY)
Truist Financial Analyst forecast on ALNY
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
07/10/26
Analysts Offer Insights on Healthcare Companies: Simulations Plus (NASDAQ: SLP), Alnylam Pharma (NASDAQ: ALNY) and Revolution Medicines (NASDAQ: RVMD)
Barclays Analyst forecast on ALNY
Eliana Merle
Barclays
Barclays
$527
Buy
70.19%
Upside
Reiterated
07/10/26
Alnylam Pharma (ALNY) Receives a Buy from Barclays
Morgan Stanley Analyst forecast on ALNY
Michael Ulz
Morgan Stanley
Morgan Stanley
$370→$400
Hold
29.17%
Upside
Reiterated
07/10/26
Alnylam price target raised to $400 from $370 at Morgan StanleyAlnylam price target raised to $400 from $370 at Morgan Stanley
Raymond James Analyst forecast on ALNY
Martin Auster
Raymond James
Raymond James
$468
Buy
51.13%
Upside
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and Alnylam Pharma (NASDAQ: ALNY)
J.P. Morgan Analyst forecast on ALNY
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Eli Lilly & Co (NYSE: LLY)
RBC Capital Analyst forecast on ALNY
Luca Issi
RBC Capital
RBC Capital
$445
Buy
43.71%
Upside
Reiterated
07/07/26
RBC Capital Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Canaccord Genuity Analyst forecast on ALNY
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$429
Buy
38.54%
Upside
Reiterated
06/29/26
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (NASDAQ: CGON), Alnylam Pharma (NASDAQ: ALNY) and Connect Biopharma Holdings (NASDAQ: CNTB)
Goldman Sachs Analyst forecast on ALNY
Salveen Richter
Goldman Sachs
Goldman Sachs
$550
Buy
77.61%
Upside
Reiterated
06/25/26
Alnylam: Buy Rating Reaffirmed as Differentiated RNAi Pipeline and Upcoming Catalysts Support Unchanged $550 Price Target
Oppenheimer Analyst forecast on ALNY
Kostas Biliouris
Oppenheimer
Oppenheimer
$500
Buy
61.47%
Upside
Reiterated
06/25/26
Oppenheimer Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Needham Analyst forecast on ALNY
Joseph Stringer
Needham
Needham
$510
Buy
64.70%
Upside
Reiterated
06/24/26
Analyst Reiterates Buy on Alnylam, Maintains $510 Price Target on Pipeline and Growth Optionality
Evercore ISI Analyst forecast on ALNY
Cory Kasimov
Evercore ISI
Evercore ISI
$400
Buy
29.17%
Upside
Reiterated
05/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Alnylam Pharma (NASDAQ: ALNY) and The Ensign Group (NASDAQ: ENSG)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on ALNY
Eric Joseph
Citi
Citi
$380
Buy
22.72%
Upside
Reiterated
07/16/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)
Stifel Nicolaus Analyst forecast on ALNY
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$444
Buy
43.38%
Upside
Reiterated
07/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (NASDAQ: ISRG), Alnylam Pharma (NASDAQ: ALNY) and Esperion (NASDAQ: ESPR)
Bank of America Securities Analyst forecast on ALNY
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$460→$410
Buy
32.40%
Upside
Reiterated
07/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Krystal Biotech (NASDAQ: KRYS)
H.C. Wainwright Analyst forecast on ALNY
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$470→$485
Buy
56.62%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Immuneering (NASDAQ: IMRX), Vera Therapeutics (NASDAQ: VERA) and Alnylam Pharma (NASDAQ: ALNY)
Truist Financial Analyst forecast on ALNY
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
07/10/26
Analysts Offer Insights on Healthcare Companies: Simulations Plus (NASDAQ: SLP), Alnylam Pharma (NASDAQ: ALNY) and Revolution Medicines (NASDAQ: RVMD)
Barclays Analyst forecast on ALNY
Eliana Merle
Barclays
Barclays
$527
Buy
70.19%
Upside
Reiterated
07/10/26
Alnylam Pharma (ALNY) Receives a Buy from Barclays
Morgan Stanley Analyst forecast on ALNY
Michael Ulz
Morgan Stanley
Morgan Stanley
$370→$400
Hold
29.17%
Upside
Reiterated
07/10/26
Alnylam price target raised to $400 from $370 at Morgan StanleyAlnylam price target raised to $400 from $370 at Morgan Stanley
Raymond James Analyst forecast on ALNY
Martin Auster
Raymond James
Raymond James
$468
Buy
51.13%
Upside
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and Alnylam Pharma (NASDAQ: ALNY)
J.P. Morgan Analyst forecast on ALNY
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Eli Lilly & Co (NYSE: LLY)
RBC Capital Analyst forecast on ALNY
Luca Issi
RBC Capital
RBC Capital
$445
Buy
43.71%
Upside
Reiterated
07/07/26
RBC Capital Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Canaccord Genuity Analyst forecast on ALNY
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$429
Buy
38.54%
Upside
Reiterated
06/29/26
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (NASDAQ: CGON), Alnylam Pharma (NASDAQ: ALNY) and Connect Biopharma Holdings (NASDAQ: CNTB)
Goldman Sachs Analyst forecast on ALNY
Salveen Richter
Goldman Sachs
Goldman Sachs
$550
Buy
77.61%
Upside
Reiterated
06/25/26
Alnylam: Buy Rating Reaffirmed as Differentiated RNAi Pipeline and Upcoming Catalysts Support Unchanged $550 Price Target
Oppenheimer Analyst forecast on ALNY
Kostas Biliouris
Oppenheimer
Oppenheimer
$500
Buy
61.47%
Upside
Reiterated
06/25/26
Oppenheimer Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Needham Analyst forecast on ALNY
Joseph Stringer
Needham
Needham
$510
Buy
64.70%
Upside
Reiterated
06/24/26
Analyst Reiterates Buy on Alnylam, Maintains $510 Price Target on Pipeline and Growth Optionality
Evercore ISI Analyst forecast on ALNY
Cory Kasimov
Evercore ISI
Evercore ISI
$400
Buy
29.17%
Upside
Reiterated
05/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Alnylam Pharma (NASDAQ: ALNY) and The Ensign Group (NASDAQ: ENSG)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OCGNOcugen
ASNDAscendis Pharma
CRBPCorbus Pharmaceuticals
ARDXArdelyx
MGTXMeiragtx Holdings
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

3 Months
Keay NakaeChardan Capital
Success Rate
25/40 ratings generated profit
63%
Average Return
+6.19%
Copying Keay Nakae's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +6.19% per trade.
1 Year
Whitney IjemCanaccord Genuity
Success Rate
19/27 ratings generated profit
70%
Average Return
+27.43%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 70.37% of your transactions generating a profit, with an average return of +27.43% per trade.
2 Years
Keay NakaeChardan Capital
Success Rate
30/40 ratings generated profit
75%
Average Return
+38.56%
Copying Keay Nakae's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +38.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALNY Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
16
20
19
24
22
Buy
32
19
17
14
16
Hold
10
6
7
6
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
58
45
43
44
45
In the current month, ALNY has received 38 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ALNY average Analyst price target in the past 3 months is 458.29.
Each month's total comprises the sum of three months' worth of ratings.

ALNY Financial Forecast

ALNY Earnings Forecast

Next quarter’s earnings estimate for ALNY is $1.61 with a range of $1.00 to $2.28. The previous quarter’s EPS was $1.51. ALNY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.
Next quarter’s earnings estimate for ALNY is $1.61 with a range of $1.00 to $2.28. The previous quarter’s EPS was $1.51. ALNY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.

ALNY Sales Forecast

Next quarter’s sales forecast for ALNY is $1.32B with a range of $1.22B to $1.39B. The previous quarter’s sales results were $1.17B. ALNY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.
Next quarter’s sales forecast for ALNY is $1.32B with a range of $1.22B to $1.39B. The previous quarter’s sales results were $1.17B. ALNY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.

ALNY Stock Forecast FAQ

What is ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 458.29.
    What is ALNY’s upside potential, based on the analysts’ average price target?
    Alnylam Pharmaceuticals has 48.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALNY a Buy, Sell or Hold?
          Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 19 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Alnylam Pharmaceuticals’s price target?
            The average price target for Alnylam Pharmaceuticals is 458.29. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $550.00 ,the lowest forecast is $380.00. The average price target represents 48.00% Increase from the current price of $309.66.
              What do analysts say about Alnylam Pharmaceuticals?
              Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of ALNY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.